A Prospective Multicenter Study on HIV-associated Hodgkin Lymphoma
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of patients with World Health Organization (WHO) grade 3 and grade 4 toxicity
30 days after termination of chemotherapy or radiotherapy
Yes
Marcus Hentrich, MD
Principal Investigator
Harlaching Hospital, Academic Teaching Hospital of the University of Munich, Department of Hematology, Oncology and Palliative Care
Germany: The Bavarian State Ministry of the Environment and Public Health
HIV-HL 2004
NCT01468740
March 2004
July 2012
Name | Location |
---|